Foreign generics will hurt local pharmaceutical sector

There are growing concerns over the movement of foreign generic makers, such as Rabaxy and Teva, to make inroads into the Korean market if a U.S.-Korea free trade agreement goes through.

This worst-case scenario, if realized, would sharply undermine the domestic pharmaceutical sector, and a market expert said the trade pact with the U.S. would not bring any great benefits to the pharmaceutic...